Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pharmacokinetics of Chronocort® Formulations in Healthy Volunteers
NCT03019614Phase 1Completed
- Sponsor
- Neurocrine Biosciences
- Start
- Mar 2010
- Primary completion
- Apr 2010
- Modality
- Small Molecules
01
Overview
Phase 1, randomised, open-label trial of hydrocortisone modified-release in congenital adrenal hyperplasia (CAH) and adrenal insufficiency (AI) (2 arms), sponsored by Neurocrine Biosciences. Primary endpoints: Time to Maximum Plasma Concentration at 24 hours, Lag Time at 24 hours and 5 more. Started Mar 2010; status: completed.
02
Drugs
hydrocortisone modified-release
03
Conditions
congenital adrenal hyperplasia (CAH)adrenal insufficiency (AI)
Beyond the preview
Go deeper on NCT03019614.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03019614.